Comments
Loading...

Syndax Pharmaceuticals Analyst Ratings

SNDXNASDAQ
Logo brought to you by Benzinga Data
$9.48
-0.21-2.17%
At close: -
$9.48
0.000.00%
After Hours: 4:58 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$51.00
Lowest Price Target1
$17.00
Consensus Price Target1
$35.81

Syndax Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:SNDX | Benzinga

Syndax Pharmaceuticals Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Syndax Pharmaceuticals Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Jan
4
Mar
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Scotiabank
Guggenheim
JP Morgan
Citigroup
HC Wainwright & Co.

1calculated from analyst ratings

Analyst Ratings for Syndax Pharmaceuticals

Buy NowGet Alert
05/06/2025Buy NowScotiabank
George Farmer42%
$16 → $17MaintainsSector PerformGet Alert
05/06/2025Buy NowGuggenheim
Michael Schmidt67%
$32 → $32ReiteratesBuy → BuyGet Alert
03/20/2025Buy NowJP Morgan
Anupam Rama59%
$39 → $41MaintainsOverweightGet Alert
03/04/2025Buy NowJP Morgan
Anupam Rama59%
$35 → $39MaintainsOverweightGet Alert
03/04/2025Buy NowCitigroup
Yigal Nochomovitz54%
$45 → $42MaintainsBuyGet Alert
03/04/2025Buy NowHC Wainwright & Co.
Edward White45%
$51 → $51ReiteratesBuy → BuyGet Alert
01/08/2025Buy NowScotiabank
George Farmer42%
$18 → $16MaintainsSector PerformGet Alert
12/10/2024Buy NowHC Wainwright & Co.
Edward White45%
$51 → $51ReiteratesBuy → BuyGet Alert
11/21/2024Buy NowJP Morgan
Anupam Rama59%
$33 → $38MaintainsOverweightGet Alert
11/19/2024Buy NowCitigroup
Yigal Nochomovitz54%
$37 → $45MaintainsBuyGet Alert
11/18/2024Buy NowHC Wainwright & Co.
Edward White45%
$49 → $51MaintainsBuyGet Alert
11/12/2024Buy NowHC Wainwright & Co.
Edward White45%
$47 → $49MaintainsBuyGet Alert
11/07/2024Buy NowGoldman Sachs
Chris Shibutani54%
$30 → $33MaintainsBuyGet Alert
11/06/2024Buy NowHC Wainwright & Co.
Edward White45%
$45 → $47MaintainsBuyGet Alert
10/24/2024Buy NowUBS
David Dai28%
→ $37Initiates → BuyGet Alert
10/14/2024Buy NowStifel
Bradley Canino40%
$40 → $41MaintainsBuyGet Alert
08/16/2024Buy NowCitigroup
Yigal Nochomovitz54%
$30 → $34MaintainsBuyGet Alert
08/15/2024Buy NowHC Wainwright & Co.
Edward White45%
$41 → $45MaintainsBuyGet Alert
08/15/2024Buy NowB of A Securities
Jason Zemansky77%
$30 → $31MaintainsBuyGet Alert
08/15/2024Buy NowBarclays
Peter Lawson42%
$32 → $33MaintainsOverweightGet Alert
08/06/2024Buy NowJP Morgan
Anupam Rama59%
$34 → $33MaintainsOverweightGet Alert
08/02/2024Buy NowHC Wainwright & Co.
Edward White45%
$41 → $41ReiteratesBuy → BuyGet Alert
07/30/2024Buy NowB of A Securities
Jason Zemansky77%
$31 → $30MaintainsBuyGet Alert
07/29/2024Buy NowHC Wainwright & Co.
Edward White45%
$41 → $41ReiteratesBuy → BuyGet Alert
06/28/2024Buy NowJefferies
Kelly Shi43%
→ $37Initiates → BuyGet Alert
06/26/2024Buy NowStifel
Bradley Canino40%
$40 → $42MaintainsBuyGet Alert
06/17/2024Buy NowHC Wainwright & Co.
Edward White45%
$41 → $41ReiteratesBuy → BuyGet Alert
06/06/2024Buy NowHC Wainwright & Co.
Edward White45%
$41 → $41ReiteratesBuy → BuyGet Alert
05/21/2024Buy NowJP Morgan
Anupam Rama59%
$34 → $34MaintainsOverweightGet Alert
05/09/2024Buy NowHC Wainwright & Co.
Edward White45%
$41 → $41ReiteratesBuy → BuyGet Alert
05/09/2024Buy NowCitigroup
Yigal Nochomovitz54%
$32 → $30MaintainsBuyGet Alert
05/09/2024Buy NowStifel
Bradley Canino40%
$39 → $40MaintainsBuyGet Alert
04/26/2024Buy NowHC Wainwright & Co.
Edward White45%
$41 → $41ReiteratesBuy → BuyGet Alert
03/28/2024Buy NowHC Wainwright & Co.
Edward White45%
$41 → $41ReiteratesBuy → BuyGet Alert
03/27/2024Buy NowHC Wainwright & Co.
Edward White45%
$41 → $41MaintainsBuyGet Alert
03/20/2024Buy NowJP Morgan
Anupam Rama59%
$31 → $34MaintainsOverweightGet Alert
02/28/2024Buy NowHC Wainwright & Co.
Edward White45%
→ $41ReiteratesBuy → BuyGet Alert
01/31/2024Buy NowScotiabank
George Farmer42%
$36 → $23DowngradeSector Outperform → Sector PerformGet Alert
01/02/2024Buy NowHC Wainwright & Co.
Edward White45%
$41 → $41ReiteratesBuy → BuyGet Alert
12/22/2023Buy NowHC Wainwright & Co.
Edward White45%
$42 → $41MaintainsBuyGet Alert
12/22/2023Buy NowMizuho
Mara Goldstein56%
→ $45Initiates → BuyGet Alert
10/26/2023Buy NowStifel
Bradley Canino40%
$38 → $36MaintainsBuyGet Alert
10/25/2023Buy NowB of A Securities
Jason Zemansky77%
→ $29Initiates → BuyGet Alert
10/17/2023Buy NowJP Morgan
Anupam Rama59%
$36 → $38MaintainsOverweightGet Alert
10/11/2023Buy NowGoldman Sachs
Chris Shibutani54%
→ $30Initiates → BuyGet Alert
10/03/2023Buy NowBaird
Joel Beatty68%
$32 → $28MaintainsOutperformGet Alert
10/02/2023Buy NowHC Wainwright & Co.
Edward White45%
$38 → $42ReiteratesBuy → BuyGet Alert
08/16/2023Buy NowJP Morgan
Anupam Rama59%
$36 → $33MaintainsOverweightGet Alert
08/04/2023Buy NowHC Wainwright & Co.
Edward White45%
→ $38Reiterates → BuyGet Alert
07/27/2023Buy NowScotiabank
George Farmer42%
→ $39Initiates → Sector OutperformGet Alert
07/26/2023Buy NowCitigroup
Yigal Nochomovitz54%
$31 → $35MaintainsBuyGet Alert
07/26/2023Buy NowBarclays
Peter Lawson42%
$31 → $34MaintainsOverweightGet Alert
07/25/2023Buy NowGuggenheim
Michael Schmidt67%
$40 → $42MaintainsBuyGet Alert
07/25/2023Buy NowB. Riley Securities
Kalpit Patel40%
$34 → $36MaintainsBuyGet Alert
07/24/2023Buy NowHC Wainwright & Co.
Edward White45%
$36 → $38ReiteratesBuy → BuyGet Alert
07/11/2023Buy NowGuggenheim
Michael Schmidt67%
→ $40Initiates → BuyGet Alert
06/26/2023Buy NowBTIG
Justin Zelin40%
$34 → $35MaintainsBuyGet Alert
05/10/2023Buy NowCitigroup
Yigal Nochomovitz54%
$32 → $31MaintainsBuyGet Alert
05/09/2023Buy NowHC Wainwright & Co.
Edward White45%
$33 → $36MaintainsBuyGet Alert
03/07/2023Buy NowJP Morgan
Anupam Rama59%
$41 → $36MaintainsOverweightGet Alert
03/02/2023Buy NowCitigroup
Yigal Nochomovitz54%
$29 → $32MaintainsBuyGet Alert
03/01/2023Buy NowGoldman Sachs
Madhu Kumar72%
$39 → $34MaintainsBuyGet Alert
03/01/2023Buy NowHC Wainwright & Co.
Edward White45%
→ $33Reiterates → BuyGet Alert
01/31/2023Buy NowStifel
Bradley Canino40%
→ $37Initiates → BuyGet Alert
01/03/2023Buy NowJP Morgan
Anupam Rama59%
→ $41Initiates → OverweightGet Alert
12/12/2022Buy NowGoldman Sachs
Madhu Kumar72%
$35 → $39MaintainsBuyGet Alert
12/12/2022Buy NowHC Wainwright & Co.
Edward White45%
$31 → $33MaintainsBuyGet Alert
08/09/2022Buy NowGoldman Sachs
Madhu Kumar72%
$40 → $35MaintainsBuyGet Alert
07/28/2022Buy NowB. Riley Securities
Kalpit Patel40%
→ $31Reinstates → BuyGet Alert

FAQ

Q

What is the target price for Syndax Pharmaceuticals (SNDX) stock?

A

The latest price target for Syndax Pharmaceuticals (NASDAQ:SNDX) was reported by Scotiabank on May 6, 2025. The analyst firm set a price target for $17.00 expecting SNDX to rise to within 12 months (a possible 79.32% upside). 26 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Syndax Pharmaceuticals (SNDX)?

A

The latest analyst rating for Syndax Pharmaceuticals (NASDAQ:SNDX) was provided by Scotiabank, and Syndax Pharmaceuticals maintained their sector perform rating.

Q

When was the last upgrade for Syndax Pharmaceuticals (SNDX)?

A

There is no last upgrade for Syndax Pharmaceuticals

Q

When was the last downgrade for Syndax Pharmaceuticals (SNDX)?

A

The last downgrade for Syndax Pharmaceuticals Inc happened on January 31, 2024 when Scotiabank changed their price target from $36 to $23 for Syndax Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Syndax Pharmaceuticals (SNDX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Syndax Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Syndax Pharmaceuticals was filed on May 6, 2025 so you should expect the next rating to be made available sometime around May 6, 2026.

Q

Is the Analyst Rating Syndax Pharmaceuticals (SNDX) correct?

A

While ratings are subjective and will change, the latest Syndax Pharmaceuticals (SNDX) rating was a maintained with a price target of $16.00 to $17.00. The current price Syndax Pharmaceuticals (SNDX) is trading at is $9.48, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch